Exogenous surfactant therapy is not standard in the @entity649 ( @entity649 ) because of a lack of proven benefit. Nonuniform surfactant distribution after either bolus or aerosol administration may be an important factor limiting response. In a previous study of @entity647 , we demonstrated that lavage administration of Exosurf (13.5 mg phospholipid/ml) was both effective and distributed uniformly in the lungs. Since the endogenous surfactant pool is much smaller than the typical dose of exogenous surfactant administered, we hypothesized that dilute surfactant preparations (4-4.5 mg phospholipid/ml) administered by lung lavage would be equally effective in reversing @entity358 in a piglet model of @entity647 . We compared three dilute surfactants: Infasurf (n = 5), KL4-Surfactant (n = 6), and Exosurf (n = 5) with controls (n = 6) and undiluted Exosurf (13. 5 mg phospholipid/ml; n = 6). All dilute surfactant preparations were effective in improving oxygenation and other parameters of pulmonary function. Surfactant administered by lavage resulted in uniform lung distribution. We conclude that dilute surfactants administered by lung lavage are effective in reversing @entity358 after @entity647 . We speculate that doses in the range of 20-40 mg phospholipid/kg may be adequate to improve lung function in @entity649 when exogenously administered surfactant is uniformly distributed in the lung.

Lavage administration of dilute surfactants after XXXX in neonatal piglets.

@entity649 :: ('MESH:D012128', 'Disease') :: ['ARDS', 'acute respiratory distress syndrome'] @entity358 :: ('MESH:D008171', 'Disease') :: ['pulmonary dysfunction'] @entity647 :: ('MESH:D055371', 'Disease') :: ['acute lung injury']
@entity647 :: (MESH:D055371,Disease) :: ['acute lung injury']
